Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

Published:2017-08-22 Issue:12 Volume:20 Page:1224-1230
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Al Sawah Sarah¹,Foster Shonda A.¹,Burge Russel¹²,Amato David¹,Schacht Alexander³,Zhu Baojin¹,Hartz Susanne⁴,Leonardi Craig⁵

Affiliation:

1. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA;

2. University of Cincinnati, Cincinnati, OH, USA;

3. Lilly Deutschland, Bad Homburg, Germany;

4. Eli Lilly and Company, Windlesham, UK;

5. Central Dermatology, St. Louis, MO, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1362413

Reference51 articles.

1. Guidelines of care for the management of psoriasis and psoriatic arthritis

2. Psoriasis prevalence among adults in the United States

3. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

4. Trends in incidence of adult-onset psoriasis over three decades: A population-based study

5. Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States;Journal of Dermatological Treatment;2024-06-24

2. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting;International Journal of Dermatology;2024-01-02

3. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany;Current Medical Research and Opinion;2023-05-23

4. Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods;Expert Review of Pharmacoeconomics & Outcomes Research;2023-03-29

5. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA;Clinical Drug Investigation;2023-02-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3